NanoGhost wins sixth Israel Innovation Authority grant for BGU cancer research

NanoGhost said June 22, 2026, that the Israel Innovation Authority awarded it another grant to fund an immuno-oncology research program with Ben-Gurion University of the Negev through BGN. The project targets immune checkpoint inhibitors and brain cancers, including glioblastoma, as NanoGhost looks to expand its targeted drug delivery platform.

Why it matters: - The grant gives NanoGhost non-dilutive funding to push its cancer drug delivery platform into new immuno-oncology research. - The collaboration targets cancers with major unmet need, including brain cancers and other hard-to-treat solid tumors. - Immune checkpoint inhibitors remain a fast-growing oncology market, making new delivery approaches commercially and clinically relevant.

What happened: - NanoGhost said on June 22, 2026, that the Israel Innovation Authority awarded the company a new grant. - The grant supports a collaborative research program with Ben-Gurion University of the Negev through its technology transfer company, BGN. - The award is the sixth grant NanoGhost has received from the Israel Innovation Authority. - Yonatan Malca, NanoGhost’s CEO, said the support could help advance new immunotherapy approaches and further validate NanoGhost’s biologics delivery platform.

The details: - The funded program will focus on next-generation immuno-oncology approaches in the field of immune checkpoint inhibitors. - The research will address cancers with significant unmet medical needs, including brain cancers. - NanoGhost said immune checkpoint inhibitors have transformed cancer treatment over the past decade. - NanoGhost also said many patients still see limited responses, disease progression or no effective treatment options, especially in aggressive cancers such as glioblastoma. - The company said the global immune checkpoint inhibitor market is worth tens of billions of dollars annually and keeps growing as immunotherapy expands across more cancer types. - NanoGhost described its platform as nano-vesicles derived from mesenchymal stem cell membranes. - The platform is designed to selectively deliver therapeutic payloads to diseased tissues, including tumors, with the goal of improving efficacy and reducing systemic toxicity. - NanoGhost said it has raised about $17 million to date, including about $4.5 million in non-dilutive grants. - The company said it is advancing multiple oncology programs and has generated promising preclinical results in several cancer indications, including brain tumors.

Between the lines: - The sixth grant suggests the Israel Innovation Authority continues to view NanoGhost as a credible bet in targeted oncology research. - The BGU partnership gives NanoGhost academic backing and a route to test whether its delivery platform can improve existing immunotherapy classes rather than inventing a new one from scratch. - The focus on brain cancers points to an area where treatment progress has been especially difficult and where better delivery methods could matter most.

What's next: - NanoGhost and BGU will use the grant to pursue research on immune checkpoint inhibitors and related immuno-oncology applications. - The company is seeking collaborations, partnerships and investment opportunities at yonatan@nano-ghost.com. - NanoGhost also directed readers to its LinkedIn page and YouTube channel.